{
  "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
  "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 45,
  "pageCount": 52,
  "prevPage": 44,
  "nextPage": 46,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide summarizes clinical trial conclusions for a pharmaceutical asset.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/45",
  "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
  "deckJsonHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7.json",
  "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-45",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.75
      },
      "kind": "list",
      "text": "Dose levels ≥ 50 mg QD may provide increased coverage of single and compound mutations in the CNS",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48283c7a-e6ea-4723-8248-f5051d8834e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.28
      },
      "kind": "list",
      "text": "In the ongoing ALKOVE-1 Phase 1 dose-escalation, NVL-655 was well tolerated. Emerging safety profile was consistent with ALK-selective, TRK-sparing design.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e84ad70-4359-4c64-bda6-b3a75b6a9176",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.81
      },
      "kind": "list",
      "text": "Phase 1 is ongoing to further understand the safety profile, PK, and preliminary efficacy, and determine the RP2D",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9478432-1203-49fb-8808-5d2ea95a7015",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.41
      },
      "kind": "list",
      "text": "This preliminary dataset indicates encouraging clinical activity in a heavily pre-treated population with ALK+ NSCLC, with responses observed in patients with and without diverse single and compound ALK resistance mutations, who have exhausted available therapies, and with brain metastases.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "faa32054-e2cc-46b9-8c52-88cfb3486cc7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.07,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Source: Lin J.J. et al., AACR-NCI-EORTC 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64bec97f-b7ad-40e4-a605-a9e1fbbd0356",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "NVL-655 is a brain-penetrant, selective inhibitor of ALK and ALK resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6faa216-f75c-4b61-991d-714c7f02784d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "CONCLUSIONS – PRELIMINARY DOSE ESCALATION DATA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7dc7313-8d76-4a6e-bdb3-6faff6f39153",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "a05f34ea-cc7d-4b29-97b9-c4dc256cb4b5",
      "evidence": "title/action-title: NVL-655 is a brain-penetrant, selective inhibitor of ALK and ALK resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}